Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. März 2018 16:01 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

SAN CARLOS, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
08. März 2018 08:01 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018

SAN CARLOS, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
07. März 2018 08:01 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March

SAN CARLOS, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
01. März 2018 08:00 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors

SAN CARLOS, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
14. Februar 2018 08:00 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

SAN CARLOS, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
29. Januar 2018 16:01 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering

SAN CARLOS, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
25. Januar 2018 07:45 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock

SAN CARLOS, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
24. Januar 2018 16:02 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock

SAN CARLOS, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating...
24. Januar 2018 16:01 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers

Three of Eight Evaluable Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with LN-145 Experienced a Confirmed Partial Response One of...
13. Dezember 2017 07:05 ET | Quelle: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017

- Generation 2 Manufacturing Process Selected for All Ongoing and Future TIL Clinical Development - - Company Reports Updated Results for Cohort 2 in Melanoma Study - - Two New Studies in...

Vorherige Seite